Increased expression and phosphorylation of GluA1 are common therapeutic targets for the treatment of depression, schizophrenia, chronic drug addiction and AD (Eastwood et al., 1997; Duman et al., 2019; Qu et al., 2021). This evidence concerns the gene GRIA1 and depressive symptom measurement.